Sera prognostics CIO Harrison Gardner is selling $119,678 worth of shares to Investing.com
In a recent filing with the Securities and Exchange Commission, Sera Prognostics, Inc. (NASDAQ:SERA), a company with a market cap of $216 million, announced that its chief information officer, Harrison Robert Gardner, has made a number of stock sales. Time is significant as InvestingPro data shows that the stock has fallen more than 23% in the past week. On January 10 and January 13, 2025, Gardner sold a total of 16,473 shares of Class A common stock through three transactions. The sales were made at prices ranging from $6.47 to $8.01 per share, for a total transaction value of $119,678. According to InvestingPro analysis, the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 2.11, indicating solid short-term financial stability.
The transactions were conducted pursuant to a Rule 10b5-1 trading plan, which Gardner adopted on May 14, 2024. Following these sales, Gardner retains ownership of 114,573 shares of Sera Prognostics. For a deeper look at SERA’s valuation and 8 additional key investment tips, check out the comprehensive analysis available at InvestingPro.
In other recent news, Sera Prognostics, a medical laboratory services company, announced that the Society for Maternal-Fetal Medicine (SMFM) has published an abstract with the main results from the PRIME study. The study’s findings, focused on improving neonatal outcomes through preterm birth risk assessment combined with clinical interventions, are due to be presented later this month. Afterward, the company plans to host a conference call and live audio webcast to discuss the study results in more detail.
On the financial front, Sera Prognostics recently reported a decrease in net income to $29,000 from $42,000 in the same quarter last year. Operating expenses rose 8% to $8.9 million, and net loss rose 10% to $7.9 million. Despite these numbers, the company maintains a strong cash reserve of $74.3 million, which is projected to sustain operations through 2027.
In an attempt to tackle rising preterm birth rates in the US, the company is focusing on increasing adoption of its PreTRM test. Executive Director Evguenia Lindgardt emphasized the importance of the imminent publication of the results of the PRIME clinical study in securing payer support and influencing clinical guidelines. These developments are part of Sera Prognostics’ strategy for commercial growth and maintaining solid cash reserves in the coming years.
This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.
